Semax: research reference

Describe the model before the result. A cellular signal, behavioral observation and clinical outcome are not interchangeable evidence labels.

Semax corresponds to the ACTH(4-7) fragment joined to Pro-Gly-Pro. Rodent studies observed changes in hippocampal BDNF and TrkB; these findings describe molecular responses and do not, by themselves, identify the peptide's binding site.

The purity value is a product-label specification, not an assay result. A batch result can only be asserted from that batch’s certificate.

These names help identify the catalog entry. A descriptive label is not evidence of efficacy, and structural identity still requires appropriate documentation.

Neuroactive peptide

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Personal protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Semax is Met-Glu-His-Phe-Pro-Gly-Pro: ACTH(4–7) joined to Pro-Gly-Pro. Some papers call it an ACTH(4–10) analog, which does not mean it is unchanged native ACTH(4–10).

The explicit sequence resolves these names and distinguishes Semax from isolated Pro-Gly-Pro or other ACTH derivatives. Evidence for a related fragment must not be presented as evidence from the same experimental material. Sources: PMID 16996037; PMID 19633950.

The 2006 study examined BDNF and TrkB in rat hippocampus, measuring mRNA, BDNF protein quantity and TrkB phosphorylation alongside a conditioned-avoidance test.

These molecular readings increased after Semax exposure in rodents. Transcript abundance, protein amount and phosphorylation answer different questions. Their agreement supports a signaling hypothesis in that tissue without identifying the peptide’s binding site or proving a uniform whole-brain effect. Sources: PMID 16996037.

The 2014 analysis examined rat cerebral cortex after permanent middle cerebral artery occlusion. Semax was associated mainly with increased expression of immune-response genes and changes in vascular-system-related genes.

The 2020 work used transient occlusion with reperfusion and RNA sequencing. Compared with saline, it found lower expression of inflammatory-process genes and higher expression of neurotransmission genes in animals.

The reported gene-group directions are not identical. Different models and designs prevent direct comparison. The difference should not be hidden under a general claim of anti-inflammatory action. Sources: PMID 24661604; PMID 32580520.

A study published in 2010 separately compared Semax and Pro-Gly-Pro in rats without surgery, with sham surgery and with focal ischemia, measuring cortical neurotrophin and receptor transcripts.

Profiles overlapped partly but differed by gene, time and experimental condition. The authors described greater ischemic-context selectivity for the Semax response. This investigates the fragment’s role without making it equivalent to the heptapeptide. Sources: PMID 19633950.

The studies support comparison of peptide identity, tissue, experimental condition and measured variable. A vascular-process-associated RNA signal alone does not demonstrate formation of functional blood vessels.

Experimental preparations do not certify Asciende’s commercial product. A shared ingredient name establishes neither formulation equivalence, stability nor experimental behavior. Compound literature and a batch certificate serve different functions. Sources: PMID 24661604; PMID 32580520; PMID 19633950.